At Innogene Kalbiotech we enrich diagnostics, therapeutics and health care by bringing in the latest breakthroughs in biology and biotechnology. Our products carry forward our mission to transforms patients’ health and lives, which we believe will work towards bettering life globally.

Our proprietory cell therapy, ReGeniC, was launched in June 2013 after approval from the Indonesian FDA. We are collaborating with 11 hospitals in Indonesia to introduce autologous stem cell therapy (from bone marrow and hematopoietic stem cells) for the treatment of osteoarthritis and heart failure, and soon we will expand to indications for stroke, spinal cord injury and bone fractures.

Also under development and trial are allogeneic stem cells from bone marrow, in collaboration with Stemedica (USA). Stem cells from Wharton jelly are in advanced development for heart indications such as myocardial infarction. Clinical trials are ongoing and commercialization has begun.